SafeBeat Celebrates AI-ECG Innovation at Annual AF Symposium, Presents Three New Abstracts
The SafeBeat Research team proudly participated in this year’s AF Symposium in Boston, commemorating three decades of pioneering advancements in atrial fibrillation (AF) care. The milestone event brought together leading experts, clinicians, and innovators committed to cardiac research and treatment.
During the symposium, SafeBeat Rx presented three new abstracts:
-
“Acute and Long-term Remote Monitoring of Antiarrhythmic Drug Titration for Atrial Fibrillation: A Case Series.”
R. Navara, M. Ferrari, A. Soi, M. Bharath, D. Corsi, A. Rathore, W. McHugh, K. Patel.
Journal of Cardiovascular Electrophysiology, 2025.
-
“Educational analysis of atrial fibrillation social media content.”
R. Navara, M. Bharath, A. Sen, R. Adhi, E. Chua, R. Desai, Y. Wang, A. Soi, N. Le, M. Ferrari, W. McHugh, K. Patel.
Journal of Cardiovascular Electrophysiology, 2025.
-
“A novel software platform for automated QTc measurements demonstrates consistent accuracy among cardiologists.”
R. Navara, M. Ferrari, Y. Wang, S. Jayakumar, M. Bharath, A. Sen, A. Soi, A. Martinez, W. McHugh, K. Patel.
Journal of Cardiovascular Electrophysiology, 2025.
The SafeBeat delegation engaged in thoughtful discussions, attended keynote sessions, and shared insights on their latest findings aimed at transforming patient outcomes. The collective passion and teamwork demonstrated throughout the event underscored the shared goal of improving the lives of those affected by AF worldwide.
About SafeBeat:
SafeBeat is a digital health company developing an ECG analysis Al model to enable patients with atrial fibrillation to take cardiac medications while being monitored by their clinical team, all from a phone. SafeBeat is backed by top early stage venture capital investors
including Y Combinator, 50 Years, Fusion Fund, and top angel investors.